Literature DB >> 26295297

Cardiotrophin-1: A new predictor of atrial fibrillation relapses after successful cardioversion.

Ibrahim Altun1, Burak Pamukcu, Cenk Eray Yildiz, Selda Can Arkaya, Goksel Guz, Akar Yilmaz, Ahmet Kaya Bilge, Umit Mutlu Turkoglu, Kamil Adalet.   

Abstract

We aimed to investigate whether or not cardiotrophin-1 (CT-1) can be used as a predictor of sinus rhythm constancy in patients with atrial fibrillation (AF) converted to sinus rhythm. Thirty two patients with AF (48-78 years), without any structural heart disease were enrolled for the study. The control group consisted of 32, age and gender matched healthy persons. Measurements of CT-1 were made after transthoracic and transesophageal echocardiography prior to cardioversion (CV). Relapses of AF were investigated by monthly electrocardiograms (ECGs) and ambulatory ECGs at 1st, 3rd, and 6th month. At the end of 6th month, measurements of CT-1 were repeated. At the beginning patients with AF had increased CT-1 levels when compared to controls (0.94 ± 0.32 pg/mL vs. 0.30 ± 0.12 pg/mL, [p < 0.001]). At the end of follow-up of the 32 patients, 17 (53%) had AF relapse. Age, initial duration of AF, left ventricle diameters, ejection fraction, left atrium appendix flow rates were similar among patients with and without AF relapse. However, basal left atrium diameter (4.24 ± 0.14 cm vs. 4.04 ± 0.22 cm, p = 0.005), pulmonary artery pressure (32.82 ± 5 vs. 28.60 ± 6.23 mmHg, p = 0.004) and CT-1 values (1.08 ± 0.37 vs. 0.82 ± 0.16 pg/mL, p = 0.02) were significantly increased in patients with AF relapse. Furthermore, patients with relapsed AF had higher CT-1 levels at 6th month when compared to those in sinus rhythm (1.00 ± 0.40 vs. 0.71 ± 0.23 pg/mL). We conclude that post-CV, AF relapses are more frequent among patients with increased baseline CT-1 levels, and CT-1 may be a potential predictor of AF relapse.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26295297      PMCID: PMC4593931          DOI: 10.17305/bjbms.2015.503

Source DB:  PubMed          Journal:  Bosn J Basic Med Sci        ISSN: 1512-8601            Impact factor:   3.363


  28 in total

1.  Is plasma cardiotrophin-1 a marker of hypertensive heart disease?

Authors:  Begoña López; Arantxa González; Juan J Lasarte; Pablo Sarobe; Francisco Borrás; Agnes Díaz; Joaquín Barba; Lourdes Tomás; Elisa Lozano; Manuel Serrano; Nerea Varo; Oscar Beloqui; María A Fortuño; Javier Díez
Journal:  J Hypertens       Date:  2005-03       Impact factor: 4.844

2.  Plasma cardiotrophin-1 following acute myocardial infarction: relationship with left ventricular systolic dysfunction.

Authors:  Suneel Talwar; Iain B Squire; Russell J O'brien; Paul F Downie; Joan E Davies; Leong L Ng
Journal:  Clin Sci (Lond)       Date:  2002-01       Impact factor: 6.124

3.  Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.

Authors:  K Yoshida; T Taga; M Saito; S Suematsu; A Kumanogoh; T Tanaka; H Fujiwara; M Hirata; T Yamagami; T Nakahata; T Hirabayashi; Y Yoneda; K Tanaka; W Z Wang; C Mori; K Shiota; N Yoshida; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

4.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation.

Authors:  A Frustaci; C Chimenti; F Bellocci; E Morgante; M A Russo; A Maseri
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

5.  Cardiotrophin-1 (CT-1) can protect the adult heart from injury when added both prior to ischaemia and at reperfusion.

Authors:  Zhihong Liao; Bhawanjit K Brar; Qing Cai; Anastasis Stephanou; Rhona M O'Leary; Diane Pennica; Derek M Yellon; David S Latchman
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

6.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11

7.  Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease.

Authors:  A Boldt; U Wetzel; J Lauschke; J Weigl; J Gummert; G Hindricks; H Kottkamp; S Dhein
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

8.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

Review 9.  Electrical, contractile and structural remodeling during atrial fibrillation.

Authors:  Maurits Allessie; Jannie Ausma; Ulrich Schotten
Journal:  Cardiovasc Res       Date:  2002-05       Impact factor: 10.787

10.  Expression cloning of cardiotrophin 1, a cytokine that induces cardiac myocyte hypertrophy.

Authors:  D Pennica; K L King; K J Shaw; E Luis; J Rullamas; S M Luoh; W C Darbonne; D S Knutzon; R Yen; K R Chien
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

View more
  4 in total

Review 1.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

2.  Usefulness of platelet to lymphocyte ratio for predicting recurrence of atrial fibrillation after direct current cardioversion.

Authors:  Seçkin Dereli; Adil Bayramoğlu; Osman Can Yontar
Journal:  Ann Noninvasive Electrocardiol       Date:  2018-11-10       Impact factor: 1.468

Review 3.  Regulation of Myocardial Extracellular Matrix Dynamic Changes in Myocardial Infarction and Postinfarct Remodeling.

Authors:  Alexey Ushakov; Vera Ivanchenko; Alina Gagarina
Journal:  Curr Cardiol Rev       Date:  2020

Review 4.  The Role of Interleukin-6 Family Members in Cardiovascular Diseases.

Authors:  Yongqi Feng; Di Ye; Zhen Wang; Heng Pan; Xiyi Lu; Menglong Wang; Yao Xu; Junping Yu; Jishou Zhang; Mengmeng Zhao; Shuwan Xu; Wei Pan; Zheng Yin; Jing Ye; Jun Wan
Journal:  Front Cardiovasc Med       Date:  2022-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.